- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04486391
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: BeiGene
- Phone Number: 1-877-828-5568
- Email: clinicaltrials@beigene.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
-
Fujian
-
Quanzhou, Fujian, China, 362000
- Recruiting
- Quanzhou First Affliated Hospital of Fujian Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Recruiting
- Harbin medical university cancer hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- Hunan Cancer hospital
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- Jilin cancer hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
1. Histologically confirmed cHL.Must have relapsed or refractory ( cHL and
- Has failed to achieve a response or progressed after autologous hematopoietic stem cell transplant (ASCT). or
Has received at least two prior lines of systemic chemotherapies for cHL and is not an ASCT candidate.
2. Must have measurable disease 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Must have adequate organ functions. 5. Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of study drug, and all treatment-related adverse events are stable and have either returned to baseline or Grade 0/1
Key Exclusion Criteria:
- Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma. Known central nervous system (CNS) lymphoma.
- Prior allogeneic hematopoietic stem cell transplant. ASCT or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) within 100 days of first dose of study drug.
- Prior therapies targeting PD-1 or PD-L1.
- Prior malignancy within the past 3 years except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
- Participant with active autoimmune disease or history of autoimmune disease with high risk of recurrence.
- Serious acute or chronic infection requiring systemic therapy.
- Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tislelizumab
Tislelizumab monotherapy for up to 45 months
|
200 mg administered via intravenous (IV) infusion once every 3 weeks
Other Names:
|
Experimental: Salvage chemotherapy
Salvage chemotherapy for up to 45 months
|
Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS) by Investigator
Time Frame: Up to 45 months
|
Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first
|
Up to 45 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR) by Investigator
Time Frame: Up to 45 months
|
The time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first
|
Up to 45 months
|
Overall Response Rate (ORR) by Investigator
Time Frame: Up to 45 months
|
The proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR)
|
Up to 45 months
|
Rate of Complete Response (CR) by Investigator
Time Frame: Up to 45 months
|
The proportion of participants who achieves a best overall response of CR
|
Up to 45 months
|
Time to Response (TTR) by Investigator
Time Frame: Up to 45 months
|
Time from the date of randomization to the time the response criteria are first met
|
Up to 45 months
|
Overall survival (OS)
Time Frame: Up to 45 months
|
Defined as the time from the date of randomization to the date of death due to any reason
|
Up to 45 months
|
Number of participants experiencing Adverse Events (AEs)
Time Frame: Up to 45 months
|
Up to 45 months
|
|
Number of participants experiencing Serious Adverse Events (SAEs)
Time Frame: Up to 45 months
|
Up to 45 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Xia Zhao, MD, BeiGene
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BGB-A317-314
- CTR20201517 (Registry Identifier: CDE)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Classical Hodgkin Lymphoma
-
Northwestern UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLCActive, not recruitingLymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLCActive, not recruitingClassical Hodgkin Lymphoma | Lymphocyte-Depleted Classical Hodgkin Lymphoma | Lymphocyte-Rich Classical Hodgkin Lymphoma | Mixed Cellularity Classical Hodgkin Lymphoma | Nodular Sclerosis Classical Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
-
Sun Yat-sen UniversityRecruitingClassical Hodgkin Lymphoma | Refractory or Relapsed Classical Hodgkin LymphomaChina
-
TakedaCompletedClassical Hodgkin Lymphoma | Relapsed or Refractory Classical Hodgkin LymphomaKorea, Republic of
-
GenmabRecruitingNon-Hodgkin Lymphoma | Classical Hodgkin LymphomaUnited States, Australia
-
Sun Yat-sen UniversityGuangzhou Gloria Biosciences Co., Ltd.RecruitingClassical Hodgkin LymphomaChina
-
Fondazione Italiana Linfomi ONLUSRecruitingClassical Hodgkin LymphomaItaly
-
University of CologneRecruitingClassical Hodgkin LymphomaGermany
Clinical Trials on Tislelizumab
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Peking University Cancer Hospital & InstituteRecruitingNon-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential ChemoradiationChina
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Henan Cancer HospitalNot yet recruiting
-
Shanghai Gopherwood Biotech Co., Ltd.RecruitingAdvanced Solid TumorChina
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
Fudan UniversityRecruitingRefractory Malignant AscitesChina
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
Peking UniversityRecruitingGastric Cancer | Colo-rectal CancerChina
-
Fudan UniversityNot yet recruiting